Athira Pharma, Inc. — Director's Dealing 2022

Feb 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-02-18

Reporting Person: CHURCH KEVIN (Executive VP, Research)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-18	Common Stock	M	3152	$1.19	Acquired	47566	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-18	Stock Option (Right to Buy)	$1.19	M	3152	Disposed	2027-06-18	Common Stock (3152)	Direct

Footnotes

F1: The shares subject to the option fully vested on September 1, 2017.